Eye light: Our clinical trials in an approach to dry eye patients For years patients suffering from dry eye have had few options. We have new therapies which offer complete treatment to all MGD cases through 2 patented technologies: Light Modulation/ LLT(low level light therapy) and OPE(optimized power energy)/IPL(intense pulsed light)
Purpose: To determine the clinical benefits of intense-pulsed-light therapy for the treatment of dry eye Disease caused by meibomian gland dysfunction (MGD) Methods: 40 patients with severe dry eye syndrome were treated by Eye Light at an outpatient clinic over 24 months in Damascus. To determine the clinical benefits of our study, we study: 1) Change in tear break-up time 2) Self-reported patient satisfaction 3) OSDI CHANGES
Result: Study patients were predominantly 70% female at an average age of 35 (from 16 to 60 years of age). 70% of patients improved in both eyes. 20% remained the same. % 10 worsened.
Conclusion: Combination of photobiostimulation and pulsed light to treat meibomian gland dysfunction and dry eye. It is a combination of OPE (optimized power energy), IPL (Intense pulsed light) and LLT (Low level light therapy) to treat both upper and lower eyelids. It is an easy and effective automated treatment.
